ArticleJournal of translational medicine2025
Sodium-myoinositol cotransporter-1 downstream of m6A methyltransferase WTAP exerts a potential carcinogenicity in diffuse large B-cell lymphoma progression.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiffuse large B-cell lymphoma (DLBCL) is the most common subtype of aggressive non-Hodgkin lymphoma, contributing significantly to global health and economic challenges. Sodium-myoinositol cotransporter-1 (SMIT1) acts as an oncogene in different types of cancer. This study aimed to explore [1] the role of SMIT1 in DLBCL development, and [2] whether N6-Methyladenosine (m6A) modifications were responsible for high SMIT1 expression within DLBCL tissues.
methodsExpression of SMIT1 was modulated by a eukaryotic SMIT1-expressing plasmid or a plasmid specific to SMIT1-targeting shRNA. The impacts of SMIT1 overexpression or knockdown on DLBCL cell proliferation, cell cycle, and apoptosis were evaluated using cell-counting-kit-8, flow cytometry and western blot assays. A DLBCL cell-derived tumor xenograft was established to further assess the tumorigenicity of SMIT1. qPCR, RIP-qPCR, MeRIP-qPCR, dual luciferase reporter and western blot assays were employed to explore whether high SMIT1 expression was associated with WTAP/YTHDF1-mediated m6A modifications.
resultsBioinformatics analysis showed that high SMIT1 expression in DLBCL was positively associated with poor prognosis, survival-related markers and m6A methyltransferase Wilms tumor 1-associated protein (WTAP). SMIT1 overexpression supported proliferation and cell cycle progression of DLBCL cells, while its depletion induced proliferation suppression, G1-S phase arrest and apoptosis of DLBCL cells. Decreased myo-inositol, phosphatidylinositol 4,5-bisphosphate (PIP2) and phosphatidylinositol 3,4,5-trisphosphate (PIP3) contents and AKT phosphorylation level were observed after SMIT1 silencing, yet increased after SMIT1 overexpression in DLBCL cells. In vivo, SMIT1 silencing delayed tumor growth and induced AKT inactivation. SMIT1 silencing-induced anti-DLBCL role was partly weakened by the addition of AKT agonist SC-79. Furthermore, we found that upregulation of WTAP enhanced the SMIT1 m6A and mRNA levels. WTAP-regulated SMIT1 m6A was recognized and stabilized by YTH N6-Methyladenosine RNA Binding Protein F1 (YTHDF1) m6A reader.
conclusionsOur study uncovers a novel oncogenic axis in DLBCL, where SMIT1's carcinogenic potential is epigenetically modulated by WTAP/YTHDF1-mediated m6A methylation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.